TRMT1L

Across TCGA pan-cancer cohorts, TRMT1L mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TRMT1L data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TRMT1L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRMT1L expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where TRMT1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.425	0.796	.001	21	view →
HNSC	DFS	Median	All	0.698	1.000	.020	18	view →
LUAD	OS	Quartile	All	0.948	0.762	.012	10	view →
LSCC	DFS	Tertile	All	0.928	0.368	.016	4	view →
CCRCC	OS	Median	All	0.742	1.000	.033	1	view →
GBM	DFS	Quartile	All	0.511	0.223	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TRMT1L–PDAC (DFS)

Open the PDAC breakdown →